- Multiple ongoing studies are researching the relationship between medical cannabis and cancer treatment
- The viability of clinical studies within the sector is hampered by lack of exact measurement of a patient’s intake
- RYAH Group intends to resolve this issue with the launch of it’s proprietary RYAH Smart Dry Herb Inhaler
- The company successfully delivered on its first Inhaler order in May 2021, and announced that they had received a follow-on order in November 2021
In 1980, The United States National Cancer Institute (“NCI”) began experimental distribution of a novel drug called Marinol, an oral form of THC (the primary active ingredient in cannabis), to cancer patients in San Francisco (https://ibn.fm/HE5vn). Just over a decade later, the city of San Francisco celebrated the passing of Proposition P in 1991, a revolutionary bill that legalized the use of medical cannabis within the city limits. There’s an abundance of evidence supporting the use of medical cannabis to treat cancer symptoms. Now, rather than just treating symptoms, science has begun to ask, “could cannabis be used to treat cancer itself”?
A recognized leader in volume management technology for plant-based medicine, RYAH Group (CSE: RYAH) is in the middle of the action. RYAH develops innovative IoT products that capture powerful data insights and is on a mission to to transform patient care using big data and AI to reshape understanding and uses of…
NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.